BioCryst Advancing Potential Treatment for Rare and Severely Debilitating Fibrodysplasia Ossificans Progressiva
RESEARCH TRIANGLE PARK, N.C., Jan. 05, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today that it has advanced a program exploring activin receptor-like kinase-2 (ALK2) inhibitors for treatment of Fibrodysplasia …